NIKKEI 225
38,600.72 -32.30 (-0.08%) HANG SENG
18,078.99 -256.33 (-1.40%) CRUDE OIL
82.34 +0.17 (+0.21%) GOLD FUTURES
2,377.80 +8.80 (+0.37%) DOW
39,134.76 +299.90 (+0.77%) Bitcoin GBP
50,987.73 -682.87 (-1.32%)
STTK Dec 2024 15.000 call
| Previous close | 2.7100 |
| Open | 2.7100 |
| Bid | 0.0500 |
| Ask | 1.2500 |
| Strike | 15.00 |
| Expiry date | 2024-12-20 |
| Day's range | 2.7100 - 2.7100 |
| Contract range | N/A |
| Volume | |
| Open interest | 8 |
Insider MonkeyYigal Nochomovitz Just Trimmed Price Target for Shattuck Labs, Inc. (NASDAQ:STTK)
We recently compiled a list of the Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks. In this article, we will examine how Shattuck Labs, Inc. (NASDAQ:STTK) compares to other stocks whose price targets have been recently reduced by analysts. On Tuesday, US stock futures remained stable, reflecting investor optimism following a significant rally […]
ZacksShattuck (STTK) Announces Positive Interim Data on Cancer Drug
Shattuck (STTK) will now focus on higher-risk myelodysplastic syndromes and TP53 mutant acute myeloid leukemia indications for lead candidate SL-172154, following encouraging interim data from the phase IB dose expansion study.
GlobeNewswireShattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
– Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had not yet been reached – – Observed 43% ORR in frontline TP53m AML patients, 33% CR/complete remission with incomplete hematologic recovery (CRi) and median overall survival had not yet been reached – – SL-172154 demonstrated a manageable interim safety profile in combination with AZA –
